Drug Trial Radar · NCT06782555
A Study of Evofosfamide in Combination With Zalifrelimab and Balstilimab
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
71
Planned (sponsor's estimate)
Start
Jan 8, 2025
Primary completion
Oct 2027
Study completion Jan 2028
Sponsor
- Lead sponsor
- ImmunoGenesisIndustry
- Sponsor type
- Industry
- Collaborators
- Agenus Inc.
- First posted
- Jan 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase 1/2 study is to test the overall safety, tolerability, and effectiveness of the combination investigational drugs evofosfamide, zalifrelimab, and balstilimab in treating advanced or metastatic castration-resistant prostate cancer, pancreatic cancer, and human papilloma virus (HPV)-negative squamous cell carcinoma of the head and neck (SCCHN).
Conditions
- Metastatic Prostate Cancer
- Metastatic Head and Neck Squamous Cell Carcinoma
- Metastatic Pancreatic Cancer
Interventions
EvofosfamideDrug
Evofosfamide administered on Days 1 and 8 of Cycles 1, 2, and 3.
ZalifrelimabDrug
Zalifrelimab administered on Day 8 of Cycles 1, 3, and 5.
BalstilimabDrug
Balstilimab administered every 2 weeks beginning on Day 8 of Cycle 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events including dose-limiting toxicitiesTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.